United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $549.29, for a total value of $5,492,900.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,368,398.04. The trade was a 34.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

James Edgemond also recently made the following trade(s):

• On Monday, June 8th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $547.50, for a total value of $5,475,000.00.
• On Thursday, June 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00.
• On Monday, June 1st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $547.87, for a total value of $5,478,700.00.
• On Thursday, May 28th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $565.63, for a total value of $5,656,300.00.
• On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.94, for a total value of $5,729,400.00.
• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $564.11, for a total value of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $567.31, for a total value of $5,673,100.00.
• On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.47, for a total value of $5,744,700.00.
• On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $573.03, for a total value of $5,730,300.00.
• On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $578.58, for a total value of $5,785,800.00.

United Therapeutics Stock Performance

Shares of UTHR opened at $545.96 on Friday. The stock has a 50-day moving average of $566.75 and a two-hundred day moving average of $521.34. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The stock has a market cap of $23.18 billion, a P/E ratio of 20.15, a P/E/G ratio of 1.78 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same period in the prior year, the firm posted $6.63 EPS. The business’s revenue was down 1.6% compared to the same quarter last year. Analysts predict that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on UTHR shares. Royal Bank Of Canada lowered their price target on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. HC Wainwright lifted their price target on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Finally, Cantor Fitzgerald lifted their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

Hedge Funds Weigh In On United Therapeutics

Institutional investors have recently modified their holdings of the stock. Torren Management LLC purchased a new position in shares of United Therapeutics during the 4th quarter valued at about $26,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the last quarter. WealthCollab LLC raised its stake in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. raised its stake in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the last quarter. Finally, Entrust Financial LLC purchased a new position in shares of United Therapeutics during the 4th quarter valued at about $31,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.